Dolutegravir improves physical health-related quality of life in adults with HTLV-1 infection: a randomized controlled trial
Open Access
- 28 June 2026
- journal article
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 170, 108933
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Dolutegravir Reduces Human T-Cell Lymphotropic Virus Type 1 Proviral Load and Improves Neurological Outcomes in a Phase 2 Controlled TrialClinical Infectious Diseases, 2026
- Dolutegravir use is related to lower HTLV-1 proviral load in people co-infected by HIV-1Communications Medicine, 2025
- Validation of the RAND 36-Item Health Survey questionnaire in BrazilArquivos de Gastroenterologia, 2022
- Comparison of functioning and health-related quality of life among patients with HTLV-1, HIV, and HIV-HTLV-1-coinfectionRevista da Sociedade Brasileira de Medicina Tropical, 2021
- Health state utility values in people living with HTLV-1 and in patients with HAM/TSP: The impact of a neglected disease on the quality of lifePLOS Neglected Tropical Diseases, 2020
- Interpreting Health-Related Quality of Life ScoresMedical Care, 2003
- Interpretation of Changes in Health-related Quality of LifeMedical Care, 2003
- Analysing controlled trials with baseline and follow up measurementsBMJ, 2001